成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart Sign in  
Chemical Structure| 201530-41-8 Chemical Structure| 201530-41-8

Structure of Deferasirox
CAS No.: 201530-41-8

Chemical Structure| 201530-41-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

{[proInfo.proName]}

CAS No.: 201530-41-8

,{[proInfo.pro_purity]}

Deferasirox is an oral iron chelator mainly used to reduce chronic iron overload in patients.

Synonyms: ICL 670; ; Defrijet

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Michel Y. Fares ; Maha A. Hegazy ; Ghada M. El-Sayed ; Maha M. Abdelrahmanc ; Nada S. Abdelwahab ;

Abstract: This work implements a combined experimental approach of analytical quality-by-design (AQbD) and green analytical chemistry (GAC) to develop an HPLC method for simultaneous determination of the two thalassemia drugs, deferasirox (DFX) and deferiprone (DFP), in biological fluid for the first time. This integration was designed to maximize efficiency and minimize environmental impacts, as well as energy and solvent consumption. To accomplish this goal, an analytical quality-by-design approach was performed, beginning with quality risk assessment and scouting analysis, followed by Placket–Burman design screening for five chromatographic parameters. Critical method parameters were thoroughly recognized and then optimized by using a two levels-three factors custom experimental design to evaluate the optimum conditions that achieved the highest resolution with acceptable peak symmetry within the shortest run time. The desirability function was used to define the optimal chromatographic conditions, and the optimal separation was achieved using an XBridge? HPLC RP-C18 (4.6 × 250 mm, 5 μm) column with ethanol?:?acidic water at pH 3.0 adjusted by phosphoric acid in the ratio of (70?:?30, v/v) as the mobile phase at a flow rate of 1 mL min?1 with UV detection at 225 nm at a temperature of 25 °C. Linearity was obtained over the concentration range of 0.30–20.00 μg mL?1 and 0.20–20.00 μg mL?1 for DFX and DFP, respectively, using 20.00 μg mL?1 ibuprofen (IBF) as an internal standard. The established method's greenness profile was evaluated and measured using various assessment tools, and the developed method was green. For the validation of the developed method, FDA recommendations were followed, and all the results obtained met the acceptance criteria. The suggested method was successfully used to study the pharmacokinetic parameters of DFX and DFP in rat plasma. Due to the substantial increase in bioavailability of the two iron chelating drugs, the results from this study strongly recommend their co-administration.

Purchased from AmBeed: ;

Alternative Products

Product Details of Deferasirox

CAS No. :201530-41-8
Formula : C21H15N3O4
M.W : 373.36
SMILES Code : O=C(O)C1=CC=C(N2N=C(C3=CC=CC=C3O)N=C2C4=CC=CC=C4O)C=C1
Synonyms :
ICL 670; ; Defrijet
MDL No. :MFCD09951804
InChI Key :BOFQWVMAQOTZIW-UHFFFAOYSA-N
Pubchem ID :214348

Safety of Deferasirox

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Healthy human CD34+ hematopoietic stem/progenitor cells 20 μM 14 days Increased erythroid colony formation capacity, reversed by NAC pretreatment PMC6567456
Sup-B15 100 nM 24 hours DFX significantly reduced cell viability and induced apoptosis and autophagy. PMC11047367
Molt-4 100 nM 24 hours DFX significantly reduced cell viability and induced apoptosis and autophagy. PMC11047367
Kasumi-1 leukemia cells 100 μM 24 hours Increased intracellular and mitochondrial ROS, reversed by NAC pretreatment PMC6567456
K562 leukemia cells 100 μM 24 hours Increased intracellular and mitochondrial ROS, reversed by NAC pretreatment PMC6567456
HL60 leukemia cells 100 μM 24 hours Increased intracellular and mitochondrial ROS, reversed by NAC pretreatment PMC6567456
proximal tubular cells 1 μM, 10 μM, 100 μM 24 hours To explore the effect of Deferasirox on the viability of proximal tubular cells, results showed that Deferasirox induced cell death with features of apoptosis and necrosis. PMC5282523
cardiomyocytes 1, 10, 100, 200 μM 24 hours hypoxia, 1 hour reoxygenation To investigate the inhibitory effect of Deferasirox on hypoxia/reoxygenation-induced iron overload, lipid peroxidation, and ferroptosis. Results showed that Deferasirox effectively prevented H/R-induced ferroptosis by chelating iron and suppressing iron overload and lipid peroxidation. PMC10863836
KYSE510 cells 0-20 μM 24, 48, 72 hours DFO significantly inhibited ESCC cell proliferation and colony formation in a dose- and time-dependent manner. PMC11855378
KYSE140 cells 0-20 μM 24, 48, 72 hours DFO significantly inhibited ESCC cell proliferation and colony formation in a dose- and time-dependent manner. PMC11855378
KYSE150 cells 0-20 μM 24, 48, 72 hours DFO significantly inhibited ESCC cell proliferation and colony formation in a dose- and time-dependent manner. PMC11855378
OE33 cells 0–40 μM 48 hours To assess the effect of Deferasirox on cellular iron metabolism, viability, and proliferation. Results showed that Deferasirox effectively inhibited cellular iron uptake and promoted intracellular iron mobilization, leading to reduced cellular iron levels and suppressed cellular viability and proliferation. PMC3596639
OE19 cells 0–40 μM 48 hours To assess the effect of Deferasirox on cellular iron metabolism, viability, and proliferation. Results showed that Deferasirox effectively inhibited cellular iron uptake and promoted intracellular iron mobilization, leading to reduced cellular iron levels and suppressed cellular viability and proliferation. PMC3596639
OE21 cells 0–40 μM 48 hours To assess the effect of Deferasirox on cellular iron metabolism, viability, and proliferation. Results showed that Deferasirox effectively inhibited cellular iron uptake and promoted intracellular iron mobilization, leading to reduced cellular iron levels and suppressed cellular viability and proliferation. PMC3596639
HL60 50 μM 48 hours DFX caused severe alteration of the mitochondrial network, increased mitochondrial area, shorter branch length, dysfunctional oxidative phosphorylation, reduced oxygen consumption rate and ATP synthesis PMC7589297
NB4 50 μM 48 hours DFX caused severe alteration of the mitochondrial network, increased mitochondrial area, shorter branch length, dysfunctional oxidative phosphorylation, reduced oxygen consumption rate and ATP synthesis PMC7589297
MOLM-13 50 μM 48 hours DFX caused severe alteration of the mitochondrial network, increased mitochondrial area, shorter branch length, dysfunctional oxidative phosphorylation, reduced oxygen consumption rate and ATP synthesis PMC7589297
IGROV1-R10 cells 0.1 to 50 μM 48 hours To validate the inhibitory effect of Deferasirox on the anti-apoptotic activity of Mcl-1, results showed that Deferasirox at 25 μM in combination with ABT-737 had the best cytotoxic effect, significantly inhibiting cell proliferation and inducing apoptosis. PMC8688747
A549 human lung cancer cells ≥100 μM 72 hours Evaluate the antiproliferative activity of Deferasirox and its derivatives, derivatives 8 and 9 showed the highest activity at 72 h and 24 h exposure times and produced the steepest dose-response curves. PMC8456774

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mongolian gerbils iron overload model Oral 100 mg/kg/day once daily for 12 weeks Deferasirox effectively removed cardiac iron in an iron-overloaded gerbil model, reducing cardiac iron content by 20.5% and liver iron content by 51% PMC2896322
BALB/c nu/nu mice Human oesophageal cancer xenograft model Oral 20 mg/kg Every other day for 3 weeks To assess the effect of Deferasirox on tumour growth in an oesophageal cancer xenograft model. Results showed that Deferasirox significantly suppressed tumour growth and reduced tumour iron levels. PMC3596639
Mice Tg2576 mice, JNPL3 mice (Tau/Tau), APP/Tau mice Oral 1.6 mg Three times a week for 6 months To evaluate the effects of Deferasirox on Alzheimer’s disease and tauopathy models. Results showed that Deferasirox did not significantly improve memory or motor function but may have decreased hyperphosphorylated tau levels. PMC8945800
Mice ESCC patient-derived xenograft (PDX) models Oral 20 mg/kg, 40 mg/kg once daily for 39 (LEG170) or 22 (HEG63) days DFO significantly inhibited tumor growth and reduced tumor volume without observable toxicity. PMC11855378
C57BL/6J mice myocardial ischemia/reperfusion injury model Oral 200 mg/kg single dose, 24 hours To investigate the inhibitory effect of Deferasirox on ferroptosis and myocardial injury in ischemia/reperfusion injury. Results showed that Deferasirox significantly reduced the infarct size and ameliorated adverse cardiac remodeling. PMC10863836
Wistar rats Ovariectomized rat model Oral 50 mg/kg and 100 mg/kg Once daily for 35 days To investigate the effects of Deferasirox on iron homeostasis and hematopoiesis in ovariectomized rats with iron accumulation. Results showed that Deferasirox improved histopathological changes in the uterine tissue, increased white blood cell count, and reduced serum iron levels, TIBC, ferritin, and transferrin saturation percentage. It also increased serum antioxidant capacity, reduced oxidative stress markers, and positively affected femur bone, hematopoietic cell count, volume of hematopoietic and adipose tissues in bone marrow, extramedullary hematopoiesis in the liver and spleen, and the relative expression of Hamp, Pu.1, Gata1, and Gdf11 genes related to hematopoiesis and iron metabolism. PMC11743768

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01441375 - Completed - United States, Louisiana ... More >> Tulane University New Orleans, Louisiana, United States, 70112 United States, Tennessee Universit of Tennessee Memphis, Tennessee, United States, 38163 Less <<
NCT01838291 - Completed - Cyprus ... More >> Thalassemia Center of North Cyprus Turkish Republic (KKTC) Nicosia, Cyprus Egypt Hematology Unit, El-Shatby Children Hospital, Alexandria University Alexandria, Egypt Hematology Unit, Assiut University Hospital Assiut, Egypt Ain Shams University Cairo, Egypt Hematology Unit, Mansoura University Children Hospital Mansoura, Egypt Tanta University Hospital Tanta, Egypt Hematology/Oncology Unit ; Zagazig University Children Hospital Zagazig, Egypt Zagazig University; Thalassemia Association Zagazig, Egypt Oman Department of Child Health, College of Medicine and Health Sciences, Sultan Qaboos University Hospital Muscat, Oman Saudi Arabia King Abdulaziz University Hospital (KAAUH) Jeddah, Saudi Arabia Maternity and Children's Hospital Maddinah, Saudi Arabia Turkey ?ukurova üniversitesi Tip Fakültesi, ?ocuk Hematolojie Bilim Dali Adana, Turkey Akdeniz üniversitesi Hastanesi, ?ocuk Sa?li?i, Hematolojie Klini?i Antalya, Turkey ?stanbul üniversitesi Tip. Fak. Hastanesi, ?ocuk Sa?li?i, Hematolojie Klini?i Istanbul, Turkey Less <<
NCT01795794 CDA Type I Phase 4 Unknown December 2013 -
NCT01369719 Thalassemia I... More >>ron Overload Transfusion Related Complications Less << Not Applicable Completed - Iran, Islamic Republic of ... More >> Hormozgan University of Medical Sciences (HUMS) Bandar abbas, Hormozgan, Iran, Islamic Republic of, 79145-3388 Less <<
NCT01956799 - Active, not recruiting December 2018 Italy ... More >> Ematologia, AO SS. Antonio e Biagio Alessandria, AL, Italy, 15121 Clinica di Ematologia, AOU Ospedale di Torrette Ancona, AN, Italy, 60020 Ematologia con trapianto, AOU Policlinico di Bari Bari, BA, Italy, 70124 Istituto di Ematologia e Oncologia Medica, Policlinico S.Orsola Bologna, BO, Italy, 40138 Ematologia, Spedali Civili Brescia, BS, Italy, 25123 Struttura complessa di Ematologia, ASO S.Croce e Carle Cuneo, CN, Italy, 12100 Cattedra di Ematologia Policlino Careggi Firenze, FI, Italy, 50134 Clinica Ematologica, Università di Genova Genova, GE, Italy, 16132 U.O. Clinica Medicina Interna, IRCCS San Martino IST Genova, GE, Italy, 16132 UO Ematologia e CTMO, Ospedale Civile G. da Saliceto Piacenza, PC, Italy, 29121 Ematologia, Università di Padova Padova, PD, Italy, 35128 Struttura Cattedra di Ematologia e CTMO, AOU di Parma Parma, PR, Italy, 43100 Ematologia e Centro Trapianti, Centro di Riferimento Oncologico della Basilicata Rionero in Vulture, PZ, Italy, 85028 Medicina Interna II Divisione di Ematologia, Ospedale S. Luigi Gonzaga Orbassano, TO, Italy, 10043 Ematologia 2, AOU Città della Salute e della Scienza Torino, TO, Italy, 10126 S.C.D.U. Ematologia e Terapie cellulari, Ospedale Mauriziano Torino, TO, Italy, 10128 UOC Ematologia, Ospedale S.Eugenio Roma, Italy, 00144 Policlinico A.Gemelli Roma, Italy, 00168 UOC Ematologia, AO S. Giovanni Addolorata Roma, Italy, 00184 Ematologia, AO S. Andrea Roma, Italy, 00189 Less <<
NCT01623895 - Completed - Korea, Republic of ... More >> Seoul National University Hospital Seoul, Chongno-gu, Korea, Republic of Less <<
NCT01370980 - Unknown September 2014 Switzerland ... More >> Policlinique Médicale Universitaire and Centre pluridisciplinaire d'oncologie, CHUV Recruiting Lausanne, Vaud, Switzerland, 1010 Contact: Bugnon Olivier ?? +41 21 314 48 48 ?? Olivier.Bugnon@hospvd.ch ?? Contact: Schneider Marie-Paule ?? +41 21 314 48 46 ?? Marie-Paule.Schneider@hospvd.ch Less <<
NCT02761395 AL-Hijama in Thalassmia Major Not Applicable Unknown May 2017 Egypt ... More >> Faculty of Medicine- Tanta University Completed Tanta, Gharbia, Egypt, 0000 Faculty of Medicine- Tanta University Recruiting Tanta, Gharbia, Egypt, 0000 Contact: Mohamed R El-Shanshory, MD ?? +201005680834 ?? elshanshory@gmail.com ?? Contact: Nahed M Hablas, MD ?? +201010560350 ?? nahedhablas79@gmail.com ?? Principal Investigator: Mohamed M El-Shanshory, MD ?? ?? ?? Principal Investigator: Nahed AR Hablas, MD ?? ?? ?? Principal Investigator: Salah M El Sayed, MD Less <<
NCT01349699 Systemic Inflammatory Process ... More >> Anemia Less << Not Applicable Completed - -
NCT02474420 Beta-Thalassemia ... More >> Iron Overload Less << Not Applicable Unknown June 2018 Canada, Ontario ... More >> University Health Network Recruiting Toronto, Ontario, Canada, M5G 2C4 Contact: Rebecca Leroux, RN, CCRP ?? +1-416-715-6485 ?? rebecca.leroux@uhn.ca ?? Principal Investigator: Kevin Kuo, MD, MSc, FRCPC Less <<
NCT00981370 Anemia, Sickle Cell ... More >> Transfusion Hemosiderosis Less << Phase 3 Terminated(1 consented patient... More >> never started on study drug, lost to follow up) Less << - United States, California ... More >> Childrens Hospital Los Angeles Los Angeles, California, United States, 90027 Less <<
NCT02065492 Thalassemia Phase 2 Phase 3 Completed - Pakistan ... More >> Aga Khan University Hospital Karachi, Sindh, Pakistan, 74800 Less <<
NCT00981370 - Terminated(1 consented patient... More >> never started on study drug, lost to follow up) Less << - -
NCT00901199 Thalassemia I... More >>ron Overload Less << Phase 4 Completed - United States, California ... More >> CHRCO Oakland, California, United States, 94609 Less <<
NCT01376622 - Completed - United States, California ... More >> Children's Hospital Los Angeles Los Angeles, California, United States, 90027 Less <<
NCT00061750 Beta-Thalassemia Phase 3 Completed - United States, California ... More >> Children's Hospital of Los Angeles Los Angeles, California, United States, 90027-6062 Children's Hospital Oakland Oakland, California, United States, 94609 Stanford Hospital Stanford, California, United States, 94305-5208 United States, Illinois Children's Memorial Hospital Chicago, Illinois, United States, 60614-3394 United States, Massachusetts Children's Hospital Boston Boston, Massachusetts, United States, 02115 United States, New York Weill Medical College of Cornell University New York, New York, United States, 10021 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104-4318 Less <<
NCT01927913 Transfusional Iron Overload ... More >> Iron Overload Iron Chelation Beta-thalassemia Transfusional Hemosiderosis Iron Metabolism Disorders Metabolic Diseases Less << Phase 2 Withdrawn(This study was withd... More >>rawn until the evaluation of the nonclinical rat findings is complete.) Less << - -
NCT03358498 - Not yet recruiting March 1, 2020 Egypt ... More >> Assiut University Hospital Assiut, Egypt, Assiut University71515 Less <<
NCT00061763 Beta-thalassemia ... More >> Myelodysplastic Syndromes Fanconi Syndrome Anemia, Diamond-Blackfan Anemia, Aplastic Less << Phase 2 Completed - United States, California ... More >> Children's Hospital Oakland Oakland, California, United States, 94609 Stanford Hospital Stanford, California, United States, 94305-5208 United States, Illinois Northwest Medical Specialists Arlington Heights, Illinois, United States, 60004 United States, Massachusetts Children's Hospital Boston Boston, Massachusetts, United States, 02115 United States, New York Weill Medical College of Cornell University New York, New York, United States, 10021 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104-4318 Less <<
NCT02233504 High Risk MDS or AML Patients Early Phase 1 Active, not recruiting October 2019 United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT00452660 Myelodysplastic Syndrome Phase 4 Completed - Israel ... More >> Wolfsom Medical Center Holon, Israel, 58100 Less <<
NCT00067080 Anemia, Sickle Cell Phase 2 Completed - -
NCT03659084 - Recruiting April 2020 France ... More >> Centre Hospitalier Lyon Sud Recruiting Pierre-Bénite, France Contact: Mauricette Michallet, MD ?? 0 478 86 22 20 ext +33 ?? mauricette.michallet@lyon.unicancer.fr ?? Contact: Mohamed ELHAMRI, PhD ?? 0478 86 22 20 ext +33 ?? mohamed.el-hamri@chu-lyon.fr ?? Principal Investigator: Mauricette Michallet, MD Less <<
NCT00940602 Myelodysplastic Syndromes Phase 2 Completed - -
NCT01044186 Transfusional Iron Overload Phase 2 Completed - United States, California ... More >> Children's Hospital and Research Center - Oakland Oakland, California, United States, 94609 Children's Hospital of Orange County Orange, California, United States, 92868 United States, Massachusetts Children's Hospital Boston Boston, Massachusetts, United States, 02115 United States, New York Queens Hospital Center Jamaica, New York, United States, 11432 New York Presbyterian Hospital/Weill Medical College of Cornell University New York, New York, United States, 10021 New York Methodist Hospital New York, New York, United States, 11215 United States, Ohio Cincinnatti Children's Hospital Medical center Cincinnatti, Ohio, United States, 45229 United States, Texas Novartis Investigative Site Houston, Texas, United States, 77030 Greece Novartis investigative Site Athens, Greece Italy Novartis Investigative Site Ancona, Italy Novartis Investigative Site Brindisi, Italy Novartis Investigative Site Cagliari, Italy Novartis Investigative Site Cosenza, Italy Novartis Investigative Site Firenze, Italy Novartis Investigative Site Milano, Italy Novartis Investigative Site Modena, Italy Novartis Investigative Site Napoli, Italy Novartis Investigative Site Torino, Italy Less <<
NCT01335035 Iron Overload Phase 4 Completed - Spain ... More >> Novartis Investigative Site Andalucia, Spain Novartis Investigative Site Asturias, Spain Novartis Investigative Site Canarias, Spain Novartis Investigative Site Castilla y Leon, Spain Novartis Investigative Site Cataluna, Spain Novartis Investigative Site Comunidad Valenciana, Spain Novartis Investigative Site Islas baleares, Spain Novartis Investigative Site Madrid, Spain Novartis Investigative Site Murcia, Spain Less <<
NCT00673608 Hemoglobinopathies ... More >> Myelodysplastic Syndromes Other Inherited or Acquired Anaemia MPD Syndrome Diamond-Blackfan Anemia Other Rare Anaemias Transfusional Iron Overload Less << Phase 4 Completed - Australia ... More >> Novarts Investigative Site Adelaide, Australia Novarts Investigative Site Brisbane, Australia Novarts Investigative Site Melbourne, Australia Novarts Investigative Site Sydney, Australia Less <<
NCT00873041 Non-transfusion Dependent Thal... More >>assemia Less << Phase 2 Completed - United States, California ... More >> Children's Hospital & Research Center Oakland Oakland, California, United States, 94609-1809 United States, Illinois Children's Memorial Hospital/Division of Hematology/Oncology Chicago, Illinois, United States, 60614-3394 United States, New York New York Presbyterian Hospital/Weill Medical College of Cornell University New York, New York, United States, 10021 Greece Novartis Investigative Site Athens, Greece Novartis Investigative Site Patras, Greece Novartis Investigative Site Thessaloniki, Greece Italy Novartis Investigative Site Cagliari, Italy Novartis Investigative Site Genova, Italy Novartis Investigative Site Milano, Italy Novartis Investigative Site Napoli, Italy Novartis Investigative Site Rome, Italy Lebanon Novartis Investigative Site Beirut, Lebanon Malaysia Novartis Investigative Site Ampang Selangor, Malaysia Novartis Investigative Site Kuala Lumpur, Malaysia Taiwan Novartis Investigative Site Taipei, Taiwan Thailand Novartis Investigative Site Bangkok, Thailand Turkey Novartis Investigative Site Adana, Turkey Novartis Investigative Site Ankara, Turkey Novartis Investigative Site Istanbul, Turkey Novartis Investigative Site Izmir, Turkey United Kingdom Novartis Investigative Site London, United Kingdom Less <<
NCT02198508 Beta-thalassemia Major Not Applicable Completed - -
NCT00873041 - Completed - -
NCT00171171 Beta-Thalassemia ... More >> Hemosiderosis Less << Phase 3 Completed - Egypt ... More >> Novartis Investigative Site Cairo, Egypt Lebanon Ali Taher Beirut, Lebanon, Riad El Solh 1107 2020 Oman Novartis Investigative Site Muscat, Oman Saudi Arabia Novartis Investigative Site Riyadh, Saudi Arabia Syrian Arab Republic Novartis Investigative Site Damascus, Syrian Arab Republic Less <<
NCT00600938 - Completed - -
NCT01874405 - Completed - -
NCT00117507 Myelodysplastic Syndromes ... More >> Iron Overload Less << Phase 2 Completed - United States, California ... More >> Stanford University Medical Center Stanford, California, United States, 94305-5821 United States, Michigan Karmanos Cancer Center Detroit, Michigan, United States, 48201 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030-4009 Less <<
NCT00600938 Transfusional Iron Overload ... More >> Transfusional Hemosiderosis Less << Phase 2 Completed - Canada, Ontario ... More >> Novartis Investigative Site Toronto, Ontario, Canada, M5G 1X8 China, Guangxi Novartis Investigative Site Nanning, Guangxi, China, 530021 Cyprus Novartis Investigative Site Limassol, Cyprus, 3304 Egypt Novartis Investigative Site Cairo, Egypt Novartis Investigative Site Mansoura, Egypt Italy Novartis Investigative Site Cagliari, CA, Italy, 09121 Novartis Investigative Site Genova, GE, Italy, 16128 Lebanon Novartis Investigative Site Hazmiyeh, Lebanon Taiwan Novartis Investigative Site Taipei, Taiwan, 10002 Thailand Novartis Investigative Site Bangkok, Thailand, 10330 Novartis Investigative Site Bangkok, Thailand, 10700 Turkey Novartis Investigative Site Adana, Turkey, 01330 Novartis Investigative Site Ankara, Turkey, 06100 Novartis Investigative Site Antalya, Turkey, 07070 Novartis Investigative Site Istanbul, Turkey, 34093 Novartis Investigative Site Izmir, Turkey, 35040 United Arab Emirates Novartis Investigative Site Dubai, United Arab Emirates, 9115 United Kingdom Novartis Investigative Site Leeds, West Yorkshire, United Kingdom, LS9 7TF Novartis Investigative Site Leeds, United Kingdom, LS9 7TF Novartis Investigative Site London, United Kingdom, N19 5NF Novartis Investigative Site London, United Kingdom, NW1 2PJ Less <<
NCT01273766 Acute Undifferentiated Leukemi... More >>a Adult Acute Lymphoblastic Leukemia in Remission Adult Acute Myeloid Leukemia in Remission Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Adult Grade III Lymphomatoid Granulomatosis Adult Langerhans Cell Histiocytosis Adult Nasal Type Extranodal NK/T-cell Lymphoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma Contiguous Stage II Adult Burkitt Lymphoma Contiguous Stage II Adult Diffuse Large Cell Lymphoma Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma Contiguous Stage II Adult Lymphoblastic Lymphoma Contiguous Stage II Grade 1 Follicular Lymphoma Contiguous Stage II Grade 2 Follicular Lymphoma Contiguous Stage II Grade 3 Follicular Lymphoma Contiguous Stage II Mantle Cell Lymphoma Contiguous Stage II Marginal Zone Lymphoma Contiguous Stage II Small Lymphocytic Lymphoma Cutaneous B-cell Non-Hodgkin Lymphoma de Novo Myelodysplastic Syndromes Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Hepatosplenic T-cell Lymphoma Intraocular Lymphoma Mast Cell Leukemia Myelodysplastic Syndrome With Isolated Del(5q) Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Myeloid/NK-cell Acute Leukemia Nodal Marginal Zone B-cell Lymphoma Noncontiguous Stage II Adult Burkitt Lymphoma Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma Noncontiguous Stage II Adult Lymphoblastic Lymphoma Noncontiguous Stage II Grade 1 Follicular Lymphoma Noncontiguous Stage II Grade 2 Follicular Lymphoma Noncontiguous Stage II Grade 3 Follicular Lymphoma Noncontiguous Stage II Mantle Cell Lymphoma Noncontiguous Stage II Marginal Zone Lymphoma Noncontiguous Stage II Small Lymphocytic Lymphoma Noncutaneous Extranodal Lymphoma Peripheral T-cell Lymphoma Previously Treated Myelodysplastic Syndromes Primary Myelofibrosis Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Grade III Lymphomatoid Granulomatosis Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Adult T-cell Leukemia/Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Small Lymphocytic Lymphoma Refractory Anemia Refractory Multiple Myeloma Secondary Acute Myeloid Leukemia Secondary Myelofibrosis Small Intestine Lymphoma Splenic Marginal Zone Lymphoma Stage I Adult Burkitt Lymphoma Stage I Adult Diffuse Large Cell Lymphoma Stage I Adult Diffuse Mixed Cell Lymphoma Stage I Adult Diffuse Small Cleaved Cell Lymphoma Stage I Adult Hodgkin Lymphoma Stage I Adult Immunoblastic Large Cell Lymphoma Stage I Adult Lymphoblastic Lymphoma Stage I Adult T-cell Leukemia/Lymphoma Stage I Cutaneous T-cell Non-Hodgkin Lymphoma Stage I Grade 1 Follicular Lymphoma Stage I Grade 2 Follicular Lymphoma Stage I Grade 3 Follicular Lymphoma Stage I Mantle Cell Lymphoma Stage I Marginal Zone Lymphoma Stage I Multiple Myeloma Stage I Mycosis Fungoides/Sezary Syndrome Stage I Small Lymphocytic Lymphoma Stage II Adult Hodgkin Lymphoma Stage II Adult T-cell Leukemia/Lymphoma Stage II Cutaneous T-cell Non-Hodgkin Lymphoma Stage II Multiple Myeloma Stage II Mycosis Fungoides/Sezary Syndrome Stage III Adult Burkitt Lymphoma Stage III Adult Diffuse Large Cell Lymphoma Stage III Adult Diffuse Mixed Cell Lymphoma Stage III Adult Diffuse Small Cleaved Cell Lymphoma Stage III Adult Hodgkin Lymphoma Stage III Adult Immunoblastic Large Cell Lymphoma Stage III Adult Lymphoblastic Lymphoma Stage III Adult T-cell Leukemia/Lymphoma Stage III Cutaneous T-cell Non-Hodgkin Lymphoma Stage III Grade 1 Follicular Lymphoma Stage III Grade 2 Follicular Lymphoma Stage III Grade 3 Follicular Lymphoma Stage III Mantle Cell Lymphoma Stage III Marginal Zone Lymphoma Stage III Multiple Myeloma Stage III Mycosis Fungoides/Sezary Syndrome Stage III Small Lymphocytic Lymphoma Stage IV Adult Burkitt Lymphoma Stage IV Adult Diffuse Large Cell Lymphoma Stage IV Adult Diffuse Mixed Cell Lymphoma Stage IV Adult Diffuse Small Cleaved Cell Lymphoma Stage IV Adult Hodgkin Lymphoma Stage IV Adult Immunoblastic Large Cell Lymphoma Stage IV Adult Lymphoblastic Lymphoma Stage IV Adult T-cell Leukemia/Lymphoma Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma Stage IV Grade 1 Follicular Lymphoma Stage IV Grade 2 Follicular Lymphoma Stage IV Grade 3 Follicular Lymphoma Stage IV Mantle Cell Lymphoma Stage IV Marginal Zone Lymphoma Stage IV Mycosis Fungoides/Sezary Syndrome Stage IV Small Lymphocytic Lymphoma Testicular Lymphoma Untreated Adult Acute Lymphoblastic Leukemia Untreated Adult Acute Myeloid Leukemia Waldenstrom Macroglobulinemia Less << Phase 2 Completed - United States, North Carolina ... More >> Comprehensive Cancer Center of Wake Forest University Winston-Salem, North Carolina, United States, 27157 Less <<
NCT01273766 - Completed - -
NCT02159040 High Risk MDS Phase 2 Terminated - United States, Arkansas ... More >> Hematology Oncology Services of Arkansas HOSA 2 Little Rock, Arkansas, United States, 72205 United States, California City of Hope National Medical Center Oncology Duarte, California, United States, 91010 United States, Maryland University of Maryland Medical Center UM Greenbaum Cancer Ctr (2) Baltimore, Maryland, United States, 21201 United States, New York Rochester General Hospital / Lipson Cancer Center Lipson Cancer Center Rochester, New York, United States, 14621 United States, Tennessee The Jones Clinic Germantown, Tennessee, United States, 38138 United States, Utah Utah Cancer Specialists IHO Corp Salt Lake City, Utah, United States, 84106 Less <<
NCT00879242 Beta Thalassemia Transfusion D... More >>ependent Less << Phase 2 Completed - Italy ... More >> Novartis Investigative Site Cagliari, Italy Novartis Investigative Site Orbassano, Italy Less <<
NCT02159040 - Terminated - -
NCT01326845 Myelodysplastic Syndrome ... More >> Transfusional Iron Overload Less << Phase 4 Terminated(The trial was termi... More >>nated due to insufficient enrollment.) Less << - France ... More >> Novartis Investigative Site Caen, Cedex, France, 14033 Novartis Investigative Site Brest, France, 29200 Novartis Investigative Site Limoges cedex, France, 87042 Novartis Investigative Site Pessac Cedex, France, 33604 Novartis Investigative Site Vandoeuvre les Nancy, France, 54511 Italy Novartis Investigative Site Alessandria, AL, Italy, 15100 Novartis Investigative Site Torino, TO, Italy, 10126 Novartis Investigative Site Roma, Italy, 00133 South Africa Novartis Investigative Site Bloemfontein, South Africa, 901 Spain Novartis Investigative Site Madrid, Spain, 28033 Less <<
NCT00427505 Healthy Phase 1 Completed - -
NCT00419172 Healthy Phase 1 Completed - -
NCT01326845 - Terminated(The trial was termi... More >>nated due to insufficient enrollment.) Less << - -
NCT00395629 Iron Overload ... More >> Hereditary Hemochromatosis Less << Phase 1 Phase 2 Completed - United States, California ... More >> UC Irvine/Long Beach Long Beach, California, United States, 90822 United States, Connecticut University of Connecticut Health Center Farmington, Connecticut, United States, 06030 United States, Michigan Henry Ford Health System Detroit, Michigan, United States, 48202 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri St. Louis University St. Louis, Missouri, United States, 63110 United States, New York Rochester General Hospital Rochester, New York, United States, 14625 United States, North Carolina Carolinas Medical Center Charlotte, North Carolina, United States, 28203 United States, Ohio Ohio State University Medical Center Columbus, Ohio, United States, 43210 United States, South Carolina Three Medical Park Columbia, South Carolina, United States, 29203 Australia Novartis Investigative Site Brisbane, Australia Canada, Ontario Novartis Investigative Site London, Ontario, Canada France Novartis Investigative Site Rennes Cedex, France Germany Novartis Investigative Site Chemnitz, Germany Novartis Investigative Site Heidelberg, Germany Novartis Investigative Site Magdeburg, Germany Novartis Investigative Site Oberhausen, Germany Italy Novartis Investigative Site Modena, Italy Novartis Investigative Site Monza, Italy Less <<
NCT01868477 - Completed - -
NCT00466063 - Completed - -
NCT00395629 - Completed - -
NCT01610297 - Completed - -
NCT01868477 Low and Int 1-risk Myelodyspla... More >>stic Syndrome Less << Phase 2 Completed - -
NCT00171821 Transfusion-dependent Iron Ove... More >>rload Less << Phase 3 Completed - -
NCT01511848 Beta-thalassemia Major ... More >> Sickle Cell Disease Iron Hemosiderosis Less << Phase 2 Phase 3 Unknown February 2013 Egypt ... More >> Pediatric Hematology clinic, Ain Shams University Not yet recruiting Cairo, Egypt Less <<
NCT00110617 Sickle Cell Disease ... More >> Iron Overload Hemolytic Anemia Less << Phase 2 Completed - -
NCT00110266 Myelodysplastic Syndrome ... More >> Iron Overload Less << Phase 2 Completed - -
NCT00749515 Transfusion-dependent Hemachro... More >>matosis Thalassemia Major Sickle Cell Disease Less << Phase 4 Completed - United States, Massachusetts ... More >> Children's Hospital Boston Boston, Massachusetts, United States, 02115 Less <<
NCT01610297 Iron Overload After Hematopoie... More >>tic Stem Cell Transplantation (HSCT) in Patients With Beta-thalassemia Major Less << Phase 4 Completed - Turkey ... More >> Novartis Investigative Site Ankara, Turkey, 06100 Novartis Investigative Site Ankara, Turkey, 06500 Novartis Investigative Site Antalya, Turkey, 07000 Novartis Investigative Site Antalya, Turkey, 07070 Novartis Investigative Site Istanbul, Turkey Novartis Investigative Site Izmir, Turkey, 35040 Less <<
NCT01058369 Myelodysplastic Syndromes Phase 2 Terminated(Insufficient patien... More >>t recruitment (only 2 patients)) Less << - Germany ... More >> Medizinische Klinik 5, Universit?tsklinikum Erlangen Erlangen, Bavaria, Germany, 91054 Less <<
NCT01718366 MDS Phase 1 Phase 2 Active, not recruiting February 2019 Belgium ... More >> GENT Gent, Belgium, 9000 France Centre Hospitalier de La Cote Basque Bayonne, France, 64100 H?pital Avicenne Bobigny, France, 93009 Centre Hospitalier de Boulogne sur Mer Boulogne sur Mer, France CHU Le Mans Le MANS, France H?pital Saint Vincent de Paul Lille, France, 59020 CHU Limoges Limoges, France, 87042 CHU Brabois Nancy, France, 54511 CHU Nantes Nantes, France, 44093 Centre Catherine de Sienne Nantes, France H?pital saint Louis Paris, France, 75010 H?pital cochin Paris, France, 75679 H?pital Necker Paris, France, 75743 CHU Poitiers Poitiers, France, 86021 IUCT Oncopole Toulouse Toulouse, France Less <<
NCT00110617 - Completed - -
NCT00235391 - Completed - -
NCT00235391 Thalassemia S... More >>ickle Cell Disease Diamond Blackfan Anemia Myelofibrosis Less << Phase 3 Completed - -
NCT00738413 Thalassemia Phase 1 Phase 2 Unknown December 2009 United States, New York ... More >> Weill Cornell Medical Center Recruiting New York, New York, United States, 10021 Contact: Robert W Grady, Ph.D. ?? 212-746-3422 ?? rwgrady@med.cornell.edu ?? Contact: Kristen Muirhead, BS ?? 212-746-3264 ?? krm2066@med.cornell.edu ?? Principal Investigator: Robert W Grady, Ph.D. ?? ?? ?? Sub-Investigator: Patricia J Giardina, M.D. Less <<
NCT01818726 Aplastic Anemia Phase 4 Completed - Russian Federation ... More >> Novartis Investigative Site Moscow, Russian Federation, 125167 Less <<
NCT00419770 - Completed - -
NCT01090323 Sickle Cell Disease Phase 2 Completed - -
NCT01090323 - Completed - -
NCT00419770 Mucormycosis Phase 2 Completed - United States, California ... More >> City of Hope National Medical Center Duarte, California, United States, 91010 UCSF San Francisco, California, United States, 94143 United States, Florida University of Miami Miami, Florida, United States, 33136 United States, North Carolina Duke University Durham, North Carolina, United States, 27710 United States, Ohio Summa Health Systems Akron, Ohio, United States, 44304 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Washington Fred Hutchinson Cancer Research Center Seattle, Washington, United States, 98109 Less <<
NCT01825512 Chronic Iron Overload Phase 3 Completed - Albania ... More >> Hospital 'Ihsan ?abej' Lushnj?, Albania Qendra Spitalore Universitare "Nene Tereza" Tirane Tirana, Albania Cyprus Department of Medical and Public health Services of the Ministry of Health Nicosia, Cyprus Egypt Alexandria University Hospital - Faculty of Medicine Alexandria, Egypt Cairo University Faculty of Medicine Cairo, Egypt Zagazig University Hospitals Zagazig, Egypt Greece National And Kapodistrian University of Athens Athens, Greece Italy Centro di Thalassemia, Ospedale Civile di Lentini Lentini, SR, Italy Università di Bari - Facoltà di Medicina Bari, Italy ASL Cagliari Ospedale Regionale per le Microcitemie Cagliari, Italy Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione Garibaldi Catania, Italy Presidio Ospedaliero "Annunziata", Centro di Studi della Microcitemia Cosenza, Italy A.O.Universitaria Meyer Firenze, Italy Clinica Pediatrica Policlinico di Modena Modena, Italy Azienda Ospedaliera di Rilievo Nazionale "Antonio Cardarelli" Napoli, Italy Azienda Ospedaliera di Padova Padova, Italy Ospedale Di Cristina Palermo, Italy Ospedali Riuniti Villa Sofia - Cervello Palermo, Italy Clinica Pediatrica Università - ASL 1 D.H per Talassemia Sassari, Italy Tunisia Centre National de Greffe de Moelle Osseuse Tunis Tunis, Tunisia United Kingdom Barts Health NHS Trust London, United Kingdom Queen's Hospital Romford, United Kingdom Less <<
NCT00379483 Transfusional Iron Overload Phase 2 Completed - Italy ... More >> Novartis Investigative Site Cagliari, Italy Novartis Investigative Site Genova, Italy Novartis Investigative Site Milan, Italy Novartis Investigative Site Torino, Italy Less <<
NCT02125877 - Completed - -
NCT00447694 Beta-thalassemia ... More >> Iron Overload Less << Phase 2 Completed - United States, California ... More >> Childrens Hospital of Los Angeles Los Angeles, California, United States, 90027 Children's Hospital and Research Center at Oakland Oakland, California, United States, 94609 United States, Illinois Children's Memorial Hospital Chicago, Illinois, United States, 60614 Less <<
NCT02413021 Acute Myeloid Leukemia ... More >> Acute Lymphoid Leukemia Less << Phase 1 Unknown October 2016 -
NCT00654589 Iron Overload Phase 4 Completed - Germany ... More >> Novartis Investigative Site Leipzig, Germany Less <<
NCT02125877 Chronic Iron Overload Due to T... More >>ransfusion-dependant Anemias Less << Phase 2 Completed - -
NCT01254227 Cardiac Iron Overload Phase 2 Completed - Canada, Ontario ... More >> Novartis Investigative Site Toronto, Ontario, Canada, M5G 2C4 Egypt Novartis Investigative Site Cairo, Egypt Greece Novartis Investigative Site Athens, GR, Greece, GR-115 27 Novartis Investigative Site Patra - RIO, GR, Greece, 265 04 Italy Novartis Investigative Site Cagliari, CA, Italy, 09121 Novartis Investigative Site Genova, GE, Italy, 16128 Novartis Investigative Site Napoli, Italy, 80138 Taiwan Novartis Investigative Site Taipei, Taiwan, 10002 Thailand Novartis Investigative Site Bangkok, Thailand, 10330 Novartis Investigative Site Bangkok, Thailand, 10700 Turkey Novartis Investigative Site Adana, Turkey, 01330 Novartis Investigative Site Antalya, Turkey, 07070 Novartis Investigative Site Istanbul, Turkey, 34093 Novartis Investigative Site Izmir, Turkey, 35040 United Kingdom Novartis Investigative Site London, United Kingdom, NW1 2BU Less <<
NCT00171210 - Completed - -
NCT00390858 Transfusional Iron Overload ... More >> β-thalassemia Major Pediatric Rare Anemia Less << Phase 2 Completed - France ... More >> Novartis Investigative Site Lyon, France Italy Novartis Investigative Site Cagliari, Italy Novartis Investigative Site Genova, Italy Novartis Investigative Site Torino, Italy Less <<
NCT00390858 - Completed - -
NCT00171210 Transfusional Iron Overload in... More >> β-thalassemia Less << Phase 3 Completed - -
NCT00599326 Porphyria Cutanea Tarda Phase 3 Completed - United States, Texas ... More >> UT Southwestern Medical Center at Dallas - Dermatology Clinical Trials Dallas, Texas, United States, 75390-8802 Less <<
NCT00171301 - Completed - -
NCT00481143 Myelodysplastic Syndromes ... More >> Transfusion Dependent Iron Overload Less << Phase 4 Completed - Germany ... More >> Novartis Investigative Site Berlin, Germany, 12200 Less <<
NCT00469560 Myelodysplastic Syndromes ... More >> Hemosiderosis Less << Phase 3 Completed - Italy ... More >> SOC EMATOLOGIA ASO SS Antonio e Biagio Alessandria, Italy Ist.Ematologia e Oncologia Medica L.e A. Seragnoli Bologna, Italy CTMO-Ematologia Ospedale Binaghi Cagliari, Italy Ospedale "A. Businco" Cagliari, Italy Oncoematologia "A.O.R.N. S'Anna e S.Sebastiano" Caserta, Italy US Dipartimentale Centro per le Malattie del Sangue Castelfranco Veneto, Italy Università di Catania - Cattedra di Ematologia - Ospedale "Ferrarotto" Catania, Italy Policlinico di Careggi, Università delgi studi di Firenze Firenze, Italy Clinica Ematologica - Università degli Studi Genova, Italy Divisione di Ematologia e TMO - Ospedale "A. Cardarelli "- Azienda Ospedaliera di Rilievo Nazionale "A. Cardarelli" Napoli, Italy Clinica Ematol Università di Perugia, Policlinico Monteluce Perugia, Italy Ematologia- Università degli Studi "La Sapienza" Roma, Italy Università Cattolica del Sacro Cuore Roma, Italy Università degli Studi di Tor Vergata Roma, Italy Istituto di Ematologia - IRCCS Ospedale Casa Sollievo della Sofferenza San Giovanni Rotondo, Italy U.O. Ematologia, Azienda Ospedaliera Universitaria Senese Siena, Italy Ospedale Civile SS. Giovanni e Paolo Venezia, Italy Less <<
NCT01278056 Non-alcoholic Steatohepatitis ... More >> Increased Iron Storage / Disturbed Distribution Less << Phase 1 Phase 2 Completed - Germany ... More >> Zollernalbklinikum Balingen/Hechingen, Germany, 72336 Charité, Virchow Klinikum Berlin, Germany, 13353 Klinikum der J. W. Goethe-Universit?t, Med. Klinik I Frankfurt, Germany, 60590 Universit?tsklinikum Halle, Klinik & Poliklinik für Innere Medizin I Halle, Germany, 06097 Universit?tsklinikum des Saarlandes Homburg/Saar, Germany, 66421 Universit?tsklinikum Magdeburg, Klinik für Gastroenterologie, Hepatologie und Infektiologie Magdeburg, Germany, 39120 Universit?tsklinikum Mainz, I. Medizinische Klinik und Poliklinik Mainz, Germany, 55131 Universit?tsklinikum Regensburg, Klinik und Poliklinik für Innere Med. I Regensburg, Germany, 93042 Universit?tsklinikum Tübingen, Medizinische Klinik IV Tübingen, Germany, 72076 Less <<
NCT00171301 Beta-thalassemia Major ... More >> Hemosiderosis Iron Overload Rare Anemia Less << Phase 4 Completed - Egypt ... More >> Novartis Investigative Site Cairo, Egypt Lebanon Novartis Investigative Site Beirut, Lebanon Oman Novartis Investigative Site Muscat, Oman Saudi Arabia Novartis Investigative Site Riyadh, Saudi Arabia Syrian Arab Republic Novartis Investigative Site Damascus, Syrian Arab Republic Less <<
NCT00564941 Myelodysplastic Syndromes ... More >> Beta-Thalassemia Less << Phase 4 Completed - Hungary ... More >> Novartis Investigative Site Budapest, Hungary Novartis Investigative Site Debrecen, Hungary Novartis Investigative Site Pecs, Hungary Novartis Investigative Site Szeged, Hungary Less <<
NCT03637556 Thalassemia Major Phase 2 Recruiting December 2019 United States, Florida ... More >> Oceane 7 Medical & Research Center, Inc. Recruiting Miami, Florida, United States, 33144 Contact: John L. Cosby, DO ?? 305-261-2738 ?? j.cosby@oceane7.us ?? Principal Investigator: John L. Cosby, DO Less <<
NCT03387475 Myelodysplasia Phase 2 Recruiting June 2020 France ... More >> CHU de GRENOBLE ALPES Recruiting Grenoble, France, 38043 Contact: Sophie PARK ?? 04 76 76 27 77 ?? SPark@chu-grenoble.fr Less <<
NCT02069886 Thalassemia (Transfusion Delen... More >>dent) Less << Phase 4 Withdrawn December 2018 -
NCT00599326 - Completed - -
NCT00631163 Chronic Anemia ... More >> Transfusional Hemosiderosis Less << Phase 2 Completed - Japan ... More >> Novartis Investigative Site Nagoya, Aichi, Japan, 453-8511 Novartis Investigative Site Nagoya, Aichi, Japan, 466-8560 Novartis Investigative Site Fukuoka-city, Fukuoka, Japan, 814-0180 Novartis Investigative Site Sapporo-city, Hokkaido, Japan, 060-8543 Novartis Investigative Site Nishinomiya, Hyogo, Japan, 663-8501 Novartis Investigative Site Kahoku-gun, Ishikawa, Japan, 920-0293 Novartis Investigative Site Kanazawa, Ishikawa, Japan, 920-8641 Novartis Investigative Site OsakaSayama, Osaka, Japan, 589-8511 Novartis Investigative Site Suita-city, Osaka, Japan, 565-0871 Novartis Investigative Site Shimotsuka-gun, Tochigi, Japan, 321-0293 Novartis Investigative Site Simotsuke-city, Tochigi, Japan, 329-0498 Novartis Investigative Site Bunkyo-ku, Tokyo, Japan, 113-8655 Novartis Investigative Site Cyuo-ku, Tokyo, Japan, 104-8560 Novartis Investigative Site Minato-ku, Tokyo, Japan, 108-8639 Novartis Investigative Site Shinagawa-ku, Tokyo, Japan, 141-8625 Novartis Investigative Site Shinjuku-ku, Tokyo, Japan, 160-0023 Novartis Investigative Site Shinjuku-ku, Tokyo, Japan, 162-8666 Novartis Investigative Site Hiroshima, Japan, 734-8551 Novartis Investigative Site Kumamoto, Japan, 860-0811 Novartis Investigative Site Kyoto, Japan, 606-8507 Novartis Investigative Site Nagasaki, Japan, 852-8501 Novartis Investigative Site Toyama, Japan, 930-8550 Poland Novartis Investigative Site Warszawa, Poland, 02-097 Novartis Investigative Site Warszawa, Poland, 02-776 Singapore Novartis Investigative Site Singapore, Singapore, 169608 Spain Novartis Investigative Site Salamanca, Castilla y Leon, Spain, 37007 Novartis Investigative Site Valencia, Spain, 46026 Turkey Novartis Investigative Site Adana, Turkey, 01330 Novartis Investigative Site Ankara, Turkey, 06100 Novartis Investigative Site Istanbul, Turkey, 34093 Novartis Investigative Site Izmir, Turkey, 35040 Less <<
NCT00303329 Anemia Hemosi... More >>derosis Less << Phase 2 Completed - United States, California ... More >> Children's Hospital and Research center at Oakland Oakland, California, United States, 94609-1809 Stanford Hospital Stanford, California, United States, 94305 United States, Massachusetts Childres's Hospital Boston Boston, Massachusetts, United States, 02115 United States, New York New York Presbyterian Hospital New York, New York, United States, 10021 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104-4399 Belgium Novartis Investigative Site Brugge, Belgium Novartis Investigative Site Bruxelles, Belgium Novartis Investigative Site Gent, Belgium Novartis Investigative Site La Louvière, Belgium Novartis Investigative Site Leuven, Belgium Canada Novartis Investigative Site Montreal, Canada Novartis Investigative Site Toronto, Canada France Novartis Investigative Site Creteil, France Novartis Investigative Site Le Kremlin Bicetre, France Novartis Investigative Site Lille, France Novartis Investigative Site Troyes, France Germany Novartis Investigative Site Duesseldorf, Germany Novartis Investigative Site Hannover, Germany Novartis Investigative Site Ulm, Germany Italy Novartis Investigative Site Bologna, Italy Novartis Investigative Site Brindisi, Italy Novartis Investigative Site Cagliari, Italy Novartis Investigative Site Genova, Italy Novartis Investigative Site Milan, Italy Novartis Investigative Site Pavia, Italy Novartis Investigative Site Rome, Italy Novartis Investigative Site Torino, Italy United Kingdom Novartis Investigative Site London, United Kingdom Less <<
NCT00432627 Hepatic Impairment Phase 1 Completed - Germany ... More >> Novartis Investigative Site Kiel, Germany Less <<
NCT00602446 - Terminated(Due to slow accrual... More >> of patients) Less << - -
NCT01394029 - Completed - Egypt ... More >> Novartis Investigative Site Cairo, Egypt, 11566 Novartis Investigative Site Cairo, Egypt Jordan Novartis Investigative Site Amman, Jordan, 11195 Spain Novartis Investigative Site Oviedo, Asturias, Spain, 33006 Novartis Investigative Site Barcelona, Catalu?a, Spain, 08916 Novartis Investigative Site Barcelona, Catalu?a, Spain United Kingdom Novartis Investigative Site West Midlands, Birmingham, United Kingdom, B4 6NH Novartis Investigative Site London, United Kingdom, N18 1QX Novartis Investigative Site London, United Kingdom, N19 5NF Novartis Investigative Site London, United Kingdom, SE5 9RS Less <<
NCT00303329 - Completed - -
NCT00560820 β-thalassemia ... More >> Transfusional Iron Overload Less << Phase 1 Completed - Italy ... More >> Novartis Investigative Site Cagliari, CA, Italy, 09121 Novartis Investigative Site Genova, GE, Italy, 16128 Novartis Investigative Site Orbassano, Italy, 10043 Less <<
NCT01033747 Liver Iron Overload Phase 2 Phase 3 Completed - Italy ... More >> Novartis Investigative Site Cagliari, Italy Novartis Investigative Site Genova, Italy Novartis Investigative Site Milan, Italy Novartis Investigative Site Torino, Italy Less <<
NCT01709032 Thalassemia Major With Severe ... More >>Transfusional Iron Overload Less << Phase 1 Phase 2 Active, not recruiting August 2017 United States, Illinois ... More >> Ann & Robert H. Lurie Children's Hospital of Chicago Chicago, Illinois, United States, 60611 United States, Pennsylvania Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States, 19104 Less <<
NCT02854722 Postmenopausal Osteoporosis Phase 2 Recruiting June 15, 2020 China, Jiangsu ... More >> Second Affiliated Hospital of Soochow University Recruiting Suzhou, Jiangsu, China, 215004 Contact: Youjia Xu, Ph.D,M.D. ?? +86 512 67783346 ?? xuyoujia@medmail.com.cn ?? Principal Investigator: You-Jia Xu, Ph.D,M.D. ?? ?? ?? Sub-Investigator: Bin Chen, M.D. ?? ?? ?? Sub-Investigator: Guang-fei Li, M.D. ?? ?? ?? Sub-Investigator: Guang-si Shen, Ph.D Less <<
NCT01033747 - Completed - -
NCT01250951 Myelodysplastic Syndrome ... More >> Thalassemia Less << Phase 4 Completed - Russian Federation ... More >> Novartis Investigative Site Moscow, Russian Federation Novartis Investigative Site Saint-Petersburg, Russian Federation Novartis Investigative Site St. Petersburg, Russian Federation Less <<
NCT00602446 Breast Cancer ... More >> Iron Overload Leukemia Lymphoma Multiple Myeloma and Plasma Cell Neoplasm Myelodysplastic Syndromes Neuroblastoma Ovarian Cancer Less << Phase 2 Terminated(Due to slow accrual... More >> of patients) Less << - United States, Minnesota ... More >> Masonic Cancer Center at University of Minnesota Minneapolis, Minnesota, United States, 55455 Less <<
NCT01284946 Porphyria Cutanea Tarda Phase 2 Unknown December 2012 France ... More >> Hopital Louis Mourier, GI unit, Recruiting Colombes, Ile de France, France, 92700 Contact: Benoit Coffin, Professor ?? 33147606061 ?? benoit.coffin@lmr.aphp.fr ?? Principal Investigator: Deybach Jean-Charles, Professor Less <<
NCT02720536 Chronic Iron Overload Phase 3 Active, not recruiting July 2, 2019 Austria ... More >> Novartis Investigative Site Vienna, Austria, 1140 Greece Novartis Investigative Site Athens, GR, Greece, GR-115 27 Novartis Investigative Site Patra - RIO, GR, Greece, 265 04 Novartis Investigative Site Thessaloniki, GR, Greece, 546 42 Italy Novartis Investigative Site Catania, CT, Italy, 95125 Novartis Investigative Site Cona, FE, Italy, 44100 Novartis Investigative Site Genova, GE, Italy, 16128 Novartis Investigative Site Cagliari, ITA, Italy, 09121 Novartis Investigative Site Lecce, LE, Italy, 73100 Novartis Investigative Site Milano, MI, Italy, 20122 Novartis Investigative Site Palermo, PA, Italy, 90127 Novartis Investigative Site Palermo, PA, Italy, 90146 Novartis Investigative Site Verona, VR, Italy, 37126 Novartis Investigative Site Napoli, Italy, 80138 Less <<
NCT01905774 - Completed - Israel ... More >> Ha'Emek Medical Center Afula, Israel, 18101 Less <<
NCT01892644 Hemochromatosis ... More >> Myelodysplastic Syndromes Less << Phase 2 Terminated(Failure to recruit ... More >>patients with hemochromatosis to the Deferasirox arm) Less << - Norway ... More >> Haukeland University Hospital, Clinical Trial Unit Bergen, Norway, 5021 Less <<
NCT02341495 Acute Myeloid Leukemia Phase 2 Recruiting January 2019 United States, Illinois ... More >> Loyola University Cardinal Bernardin Cancer Center Recruiting Maywood, Illinois, United States, 60153 Principal Investigator: Elizabeth Henry, MD ?? ?? ?? Sub-Investigator: Sucha Nand, MD Less <<
NCT02038816 Myelodysplastic Syndromes Phase 2 Terminated(accrual too slow, i... More >>nsufficient patients) Less << - Canada, Ontario ... More >> Odette Cancer Centre, Sunnybrook Health Sciences Centre Toronto, Ontario, Canada, M4N 3M5 Less <<
NCT01159067 Iron Overload ... More >> Accelerated Phase Chronic Myelogenous Leukemia Adult Acute Lymphoblastic Leukemia in Remission Adult Acute Myeloid Leukemia in Remission Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Adult Acute Myeloid Leukemia With Del(5q) Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) Atypical Chronic Myeloid Leukemia, BCR-ABL Negative Blastic Phase Chronic Myelogenous Leukemia Chronic Eosinophilic Leukemia Chronic Myelomonocytic Leukemia Chronic Neutrophilic Leukemia Chronic Phase Chronic Myelogenous Leukemia de Novo Myelodysplastic Syndromes Disseminated Neuroblastoma Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable Nodal Marginal Zone B-cell Lymphoma Noncontiguous Stage II Adult Burkitt Lymphoma Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma Noncontiguous Stage II Adult Lymphoblastic Lymphoma Noncontiguous Stage II Grade 1 Follicular Lymphoma Noncontiguous Stage II Grade 2 Follicular Lymphoma Noncontiguous Stage II Grade 3 Follicular Lymphoma Noncontiguous Stage II Mantle Cell Lymphoma Noncontiguous Stage II Marginal Zone Lymphoma Noncontiguous Stage II Small Lymphocytic Lymphoma Poor Prognosis Metastatic Gestational Trophoblastic Tumor Previously Treated Myelodysplastic Syndromes Primary Myelofibrosis Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Acute Myeloid Leukemia Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma Recurrent Adult Hodgkin Lymphoma Recurrent Adult Immunoblastic Large Cell Lymphoma Recurrent Adult Lymphoblastic Lymphoma Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma Recurrent Grade 1 Follicular Lymphoma Recurrent Grade 2 Follicular Lymphoma Recurrent Grade 3 Follicular Lymphoma Recurrent Malignant Testicular Germ Cell Tumor Recurrent Mantle Cell Lymphoma Recurrent Marginal Zone Lymphoma Recurrent Mycosis Fungoides/Sezary Syndrome Recurrent Neuroblastoma Recurrent Ovarian Epithelial Cancer Recurrent Ovarian Germ Cell Tumor Recurrent Small Lymphocytic Lymphoma Refractory Chronic Lymphocytic Leukemia Refractory Hairy Cell Leukemia Relapsing Chronic Myelogenous Leukemia Secondary Acute Myeloid Leukemia Secondary Myelodysplastic Syndromes Splenic Marginal Zone Lymphoma Stage I Multiple Myeloma Stage II Multiple Myeloma Stage II Ovarian Epithelial Cancer Stage III Adult Burkitt Lymphoma Stage III Adult Diffuse Large Cell Lymphoma Stage III Adult Diffuse Mixed Cell Lymphoma Stage III Adult Diffuse Small Cleaved Cell Lymphoma Stage III Adult Hodgkin Lymphoma Stage III Adult Immunoblastic Large Cell Lymphoma Stage III Adult Lymphoblastic Lymphoma Stage III Chronic Lymphocytic Leukemia Stage III Grade 1 Follicular Lymphoma Stage III Grade 2 Follicular Lymphoma Stage III Grade 3 Follicular Lymphoma Stage III Malignant Testicular Germ Cell Tumor Stage III Mantle Cell Lymphoma Stage III Marginal Zone Lymphoma Stage III Multiple Myeloma Stage III Ovarian Epithelial Cancer Stage III Small Lymphocytic Lymphoma Stage IIIA Breast Cancer Stage IIIB Breast Cancer Stage IIIC Breast Cancer Stage IV Adult Burkitt Lymphoma Stage IV Adult Diffuse Large Cell Lymphoma Stage IV Adult Diffuse Mixed Cell Lymphoma Stage IV Adult Diffuse Small Cleaved Cell Lymphoma Stage IV Adult Hodgkin Lymphoma Stage IV Adult Immunoblastic Large Cell Lymphoma Stage IV Adult Lymphoblastic Lymphoma Stage IV Breast Cancer Stage IV Chronic Lymphocytic Leukemia Stage IV Grade 1 Follicular Lymphoma Stage IV Grade 2 Follicular Lymphoma Stage IV Grade 3 Follicular Lymphoma Stage IV Mantle Cell Lymphoma Stage IV Marginal Zone Lymphoma Stage IV Ovarian Epithelial Cancer Stage IV Small Lymphocytic Lymphoma Less << Phase 2 Terminated(Low enrollment) - United States, California ... More >> City of Hope Duarte, California, United States, 91010 Less <<
NCT02663752 Myelodysplastic Syndrome Phase 2 Terminated - Belgium ... More >> Novartis Investigative Site Liege, Belgium, 4000 Less <<
NCT02435212 Transfusion-dependent Anemia Phase 2 Active, not recruiting January 19, 2024 -
NCT02663752 - Terminated - -
NCT01459718 Transfusion-dependent β-thalas... More >>semia Patients Cardiac Iron Overload Less << Phase 2 Completed - Greece ... More >> Novartis Investigative Site Athens, GR, Greece, 115 27 Novartis Investigative Site Athens, GR, Greece, GR-115 27 Novartis Investigative Site Athens, Greece, GR Novartis Investigative Site Patras, Greece, 26500 Less <<
NCT01709838 Non-transfusion Dependent Thal... More >>assemia Less << Phase 4 Active, not recruiting January 17, 2019 China, Guangxi ... More >> Novartis Investigative Site Nanning, Guangxi, China, 530021 Greece Novartis Investigative Site Athens, GR, Greece, GR-115 27 Italy Novartis Investigative Site Cagliari, CA, Italy, 09121 Novartis Investigative Site Milano, MI, Italy, 20122 Lebanon Novartis Investigative Site Hazmiyeh, Beirut, Lebanon, PO BOX 213 Thailand Novartis Investigative Site Bangkok, Thailand, 10700 Tunisia Novartis Investigative Site Tunis, Tunisia, 1006 Turkey Novartis Investigative Site Adana, Turkey, 01330 Novartis Investigative Site Istanbul, Turkey, 34093 Novartis Investigative Site Izmir, Turkey, 35040 United Kingdom Novartis Investigative Site Leicester, United Kingdom, LE1 5WW Novartis Investigative Site London, United Kingdom, NW1 2PJ Less <<
NCT01724138 β-thalassemia Major Phase 4 Withdrawn October 2014 -
NCT03203850 Hereditary Hemochromatosis Phase 2 Recruiting March 10, 2022 Belgium ... More >> Novartis Investigative Site Recruiting Leuven, Belgium, 3000 Spain Novartis Investigative Site Recruiting Manresa, Espana, Spain, 08241 Novartis Investigative Site Recruiting Barcelona, Spain, 08041 Novartis Investigative Site Recruiting Madrid, Spain, 28007 Switzerland Novartis Investigative Site Recruiting Lugano, Switzerland, 6900 Novartis Investigative Site Recruiting St Gallen, Switzerland, 9007 Less <<
NCT02943668 Anemia Myelod... More >>ysplastic Syndrome Less << Phase 2 Recruiting September 2, 2020 United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Bart L. Scott ?? 206-667-1990 ?? ?? Principal Investigator: Bart L. Scott Less <<
NCT02993224 Transfusion-dependent Thalasse... More >>mia Non-transfusion-dependent Thalassemia Less << Phase 2 Recruiting December 27, 2020 Egypt ... More >> Novartis Investigative Site Recruiting Alexandria, Egypt, 21131 Novartis Investigative Site Recruiting Cairo, Egypt, 11562 Novartis Investigative Site Recruiting Zagazig, Egypt, 44519 Lebanon Novartis Investigative Site Recruiting Hazmiyeh, Beirut, Lebanon, PO BOX 213 Saudi Arabia Novartis Investigative Site Recruiting Al Ahsa, SAU, Saudi Arabia Novartis Investigative Site Recruiting Jeddah, Saudi Arabia, 21423 Novartis Investigative Site Recruiting Jeddah, Saudi Arabia, 21589 Novartis Investigative Site Recruiting Riyadh, Saudi Arabia, 11117 Thailand Novartis Investigative Site Recruiting Bangkok noi, Bangkok, Thailand, 10700 Novartis Investigative Site Recruiting Bangkoknoi, Bangkok, Thailand, 10700 Novartis Investigative Site Recruiting Bangkok, Thailand, 10400 Turkey Novartis Investigative Site Recruiting Ankara, Turkey, 06100 Novartis Investigative Site Recruiting Antalya, Turkey, 07070 Novartis Investigative Site Recruiting Istanbul, Turkey, 34093 Less <<
NCT03372083 Iron Over Load Phase 4 Recruiting November 14, 2019 Italy ... More >> Novartis Investigative Site Recruiting Cona, FE, Italy, 44100 Novartis Investigative Site Recruiting Cagliari, ITA, Italy, 09121 Novartis Investigative Site Recruiting Napoli, Italy, 80138 Lebanon Novartis Investigative Site Recruiting Hazmiyeh, Beirut, Lebanon, PO BOX 213 Oman Novartis Investigative Site Recruiting Muscat, Oman, 123 Russian Federation Novartis Investigative Site Recruiting Moscow, Russian Federation, 117198 Thailand Novartis Investigative Site Recruiting Bangkok noi, Bangkok, Thailand, 10700 Novartis Investigative Site Completed Muang, Chiangmai, Thailand, 50200 United Arab Emirates Novartis Investigative Site Recruiting Dubai, United Arab Emirates, 9115 Less <<
NCT01948817 Focus on Transfusion Dependent... More >> Thalassemia Patients Who Are Inadequate Responders to Deferasirox > 35mg/kgQD Less << Phase 2 Withdrawn February 2016 -
NCT00845871 Transfusional Hemosiderosis Phase 4 Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.68mL

0.54mL

0.27mL

13.39mL

2.68mL

1.34mL

26.78mL

5.36mL

2.68mL
Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records